CN1838947A - 用于治疗或预防严重急性呼吸道综合征(sars)的甘草皂苷或其衍生物 - Google Patents

用于治疗或预防严重急性呼吸道综合征(sars)的甘草皂苷或其衍生物 Download PDF

Info

Publication number
CN1838947A
CN1838947A CNA2004800190316A CN200480019031A CN1838947A CN 1838947 A CN1838947 A CN 1838947A CN A2004800190316 A CNA2004800190316 A CN A2004800190316A CN 200480019031 A CN200480019031 A CN 200480019031A CN 1838947 A CN1838947 A CN 1838947A
Authority
CN
China
Prior art keywords
glycyrrhizin
sars
infection
derivatives
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800190316A
Other languages
English (en)
Chinese (zh)
Inventor
J·希纳特尔
H·W·德尔
G·胡佛
M·米歇埃里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe Universitaet Frankfurt am Main
Original Assignee
Goethe Universitaet Frankfurt am Main
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goethe Universitaet Frankfurt am Main filed Critical Goethe Universitaet Frankfurt am Main
Publication of CN1838947A publication Critical patent/CN1838947A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CNA2004800190316A 2003-06-06 2004-06-07 用于治疗或预防严重急性呼吸道综合征(sars)的甘草皂苷或其衍生物 Pending CN1838947A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47690803P 2003-06-06 2003-06-06
US60/476,908 2003-06-06

Publications (1)

Publication Number Publication Date
CN1838947A true CN1838947A (zh) 2006-09-27

Family

ID=33511824

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800190316A Pending CN1838947A (zh) 2003-06-06 2004-06-07 用于治疗或预防严重急性呼吸道综合征(sars)的甘草皂苷或其衍生物

Country Status (7)

Country Link
US (1) US20070099855A1 (https=)
EP (2) EP1660059A1 (https=)
JP (1) JP2006527185A (https=)
KR (1) KR20060025549A (https=)
CN (1) CN1838947A (https=)
CA (1) CA2527989A1 (https=)
WO (1) WO2004108122A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106420695A (zh) * 2016-09-09 2017-02-22 南京农业大学 甘草素抗猪流行性腹泻病毒感染的应用
CN112457363A (zh) * 2020-11-23 2021-03-09 华南农业大学 一种马铃薯三糖齐墩果酸皂苷衍生物及其制备方法和应用
CN115192590A (zh) * 2021-04-13 2022-10-18 北京大学 甘草皂苷a3对新型冠状病毒刺突蛋白的抑制及其药物用途
CN115867263A (zh) * 2020-05-27 2023-03-28 阿特格诺有限公司 用于治疗用途的单亚硝基化的和双亚硝基化的烷基多元醇

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009352A1 (en) * 2009-07-09 2011-01-13 Minophagen Pharmaceutical Co., Ltd. Restorative agent for antibacterial peptide production ability
CN103620025A (zh) * 2011-06-28 2014-03-05 白血球保健股份有限公司 病毒或细菌的新型稳定方法
RU2504397C1 (ru) * 2012-10-25 2014-01-20 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент рибонуклеазу и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
MX2018010198A (es) 2016-02-25 2019-06-12 Applied Biological Laboratories Inc Composiciones y metodos para proteger contra patogenos e irritantes transportados por el aire.
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
CN111084806B (zh) * 2020-02-13 2021-09-07 遵义医科大学 一种治疗或预防冠状病毒感染的药物组合物
CN111686253A (zh) * 2020-02-20 2020-09-22 田中民 一种预防和消杀冠状病毒的新方法
AU2021239983A1 (en) * 2020-03-18 2022-09-22 Flow Pharma, Inc. Injectable formulation of poly(lactic-co-glycolic (PLGA)) microspheres encapsulating siltuximab
US20230218548A1 (en) * 2020-03-19 2023-07-13 Eumentis Therapeutics, Inc. Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections
EP3888662A1 (en) * 2020-04-02 2021-10-06 Vossensteyn Compounds, compositions and devices for use in the treatment of coronavirus infections
CN112135625B (zh) * 2020-04-27 2021-07-06 广州新创忆药物临床研究有限公司 一种预防或治疗covid-19新冠肺炎的药物及其应用
EP4144363A4 (en) * 2020-04-27 2024-05-29 Guangzhou Century Clinical Research Co., Ltd Drug, food and application of anti-coronavirus infection
KR102169476B1 (ko) * 2020-05-20 2020-10-23 (주)신테카바이오 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
EP3939585A4 (en) 2020-05-20 2022-03-02 Syntekabio, Inc. PREVENTIVE OR THERAPEUTIC COMPOSITION FOR INFECTIOUS DISEASES WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
WO2022051557A1 (en) * 2020-09-02 2022-03-10 Applied Biological Laboratories, Inc. Glycyrrhizin for the treatment or prophylaxis of viral infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3873470D1 (de) * 1987-10-14 1992-09-10 Ueno Seiyaku Oyo Kenkyujo Kk Behandlung von viruskrankheiten.
US5156973A (en) * 1988-11-23 1992-10-20 Edward Shanbrom Antiviral blood sampling process and apparatus
JP3007665B2 (ja) * 1990-09-18 2000-02-07 日清製粉株式会社 コロナウィルス感染症の予防および治療剤ならびに消毒薬
RU2024542C1 (ru) * 1991-03-04 1994-12-15 Институт органической химии РАН ГЛИКОПЕПТИД β-ГЛИЦИРРИЗИНОВОЙ КИСЛОТЫ С МЕТИЛОВЫМ ЭФИРОМ ГЛИЦИЛ-L-ВАЛИНА, ПРОЯВЛЯЮЩИЙ АНТИ-СПИД-АКТИВНОСТЬ
US5356880A (en) * 1991-05-30 1994-10-18 Sanwa Kagaku Kenkyusho Co., Ltd. Glycyrrhetinic acid derivatives

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106420695A (zh) * 2016-09-09 2017-02-22 南京农业大学 甘草素抗猪流行性腹泻病毒感染的应用
CN115867263A (zh) * 2020-05-27 2023-03-28 阿特格诺有限公司 用于治疗用途的单亚硝基化的和双亚硝基化的烷基多元醇
CN112457363A (zh) * 2020-11-23 2021-03-09 华南农业大学 一种马铃薯三糖齐墩果酸皂苷衍生物及其制备方法和应用
CN115192590A (zh) * 2021-04-13 2022-10-18 北京大学 甘草皂苷a3对新型冠状病毒刺突蛋白的抑制及其药物用途
CN115192590B (zh) * 2021-04-13 2023-10-20 北京大学 甘草皂苷a3对新型冠状病毒刺突蛋白的抑制及其药物用途

Also Published As

Publication number Publication date
US20070099855A1 (en) 2007-05-03
EP1660059A1 (en) 2006-05-31
JP2006527185A (ja) 2006-11-30
WO2004108122A1 (en) 2004-12-16
CA2527989A1 (en) 2004-12-16
KR20060025549A (ko) 2006-03-21
EP1719515A2 (en) 2006-11-08
EP1719515A3 (en) 2006-11-29

Similar Documents

Publication Publication Date Title
CN1838947A (zh) 用于治疗或预防严重急性呼吸道综合征(sars)的甘草皂苷或其衍生物
CN116568688B (zh) 用于治疗病毒感染的化合物和方法
Kaddoura et al. COVID-19 therapeutic options under investigation
CN1036196C (zh) 1，3-氧硫环戊烷核苷类似物的制备方法
EA016457B1 (ru) Аналог тиофена для лечения вирусной инфекции гепатита с
US20240261307A1 (en) Inhibitors of sars-cov-2 viral replication and uses thereof
US20230248684A1 (en) Compositions and methods for treating acute respiratory distress syndrome (ards) and inflammatory disorders caused by coronaviruses and other respiratory pathogens or agents that mediate pulmonary injury, inflammation or acute respiratory distress, and related compositions and methods for treating and preventing human sars coronavirus infection, covid-19 disease and related symptoms
US20210322351A1 (en) Vidofludimus for use in the treatment or prevention of viral diseases
US11738013B2 (en) Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
CN121002033A (zh) 用于治疗病毒感染的4-氨基吡咯并[2,1-f][1,2,4]三嗪c-核苷化合物和方法
CN1703207A (zh) GSK－3β抑制剂在制备增加骨生成的药物中的应用
CN1228026A (zh) 用于治疗hiv感染的含有vx478、叠氮胸苷、ftc和/或3tc的复方制剂
CN1183915C (zh) 抑制人类免疫缺陷综合征病毒感染和增殖的药剂的用途
CN1178660C (zh) 抗病毒药物组合
CN1913892A (zh) 药物组合物及联合药物
HK1093315A (en) Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (sars)
CN1845745A (zh) 给予tlr7配体及其前药用于治疗丙型肝炎病毒感染
CN1681518A (zh) 利用l－fmau联合治疗乙型肝炎病毒感染
CN119235847B (zh) 一种化合物在制备抗流感病毒药物中的应用
Chatterjee et al. A review on SARS-CoV2 drug regimens inferring plausible mechanisms to impede the viral propagation and cytokine storm
WO2024189434A1 (en) USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2
CN1101350A (zh) 核苷衍生物及抗疱疹组合物
US20210115061A1 (en) Small-Molecule HIV-1 Capsid Protein Inhibitors and Methods Using Same
CN1235602A (zh) 1－(3－氨基吲唑－5－基)－3－苯甲基－环脲作为hiv蛋白酶抑制剂
HK40111347A (zh) 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1093315

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1093315

Country of ref document: HK